

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Piedmont Conference Room
*To arrange public building access, please
contact Ashley Ragadio at 510.373.5731*

AGENDA

ITEM	DESCRIPTION	TIME	VOTE								
I)	<p>Call to order</p> <p><i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i></p> <ul style="list-style-type: none"> Conflict of Interest Check/Disclosure Agenda Overview 	2 min	-								
II)	<p>Informational Updates</p> <p><i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Sanjay Bhatt, MD, Medical Director, Quality Improvement - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i></p> <ul style="list-style-type: none"> Staffing updates Opioid program letter and opioid BZD tapering tool update Pharmacy Cost Containment Strategy Updates Hep C Quantity Limit change from 14 day supply to 28 day supply 	15min	-								
III)	<p>Review/ Approval of previous meeting minutes</p> <p><i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i></p> <ul style="list-style-type: none"> P&T Meeting Minutes from December 11, 2018 	2 min	V								
IV)	<p>Pharmacy Utilization Reports (Quarter 1)</p> <p><i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i></p> <ul style="list-style-type: none"> Top 50 Drugs by Cost Top 100 PA Reviewed Drugs <p>Consent Agenda</p> <p><i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <i>Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx</i> <i>(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)</i></p> <table border="1" data-bbox="313 1528 1177 1680"> <thead> <tr> <th>Monograph/Class Reviews</th> <th>Changes</th> </tr> </thead> <tbody> <tr> <td>Methergine Monograph</td> <td> <ul style="list-style-type: none"> No changes </td> </tr> <tr> <th colspan="2">Interim Formulary changes</th> </tr> <tr> <td colspan="2"> <ul style="list-style-type: none"> See p. XX in packet </td> </tr> </tbody> </table>	Monograph/Class Reviews	Changes	Methergine Monograph	<ul style="list-style-type: none"> No changes 	Interim Formulary changes		<ul style="list-style-type: none"> See p. XX in packet 		20 min	V <i>(on each topic)</i>
Monograph/Class Reviews	Changes										
Methergine Monograph	<ul style="list-style-type: none"> No changes 										
Interim Formulary changes											
<ul style="list-style-type: none"> See p. XX in packet 											
	<p>Pharmacy Policies & Procedures Updates</p> <ul style="list-style-type: none"> RX-002 - PA Review Process 										

ADJOURN TO CLOSED SESSION (Pursuant to California Government Code Title 5, §54954.5(h))

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes
Estimated Date of Public Disclosure: March 2019 (formulary changes only; no trade secrets will be disclosed).

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx

- Tranexamic Acid Criteria
- Moxifloxacin Criteria
- Linezolid Criteria
- Criteria for short-acting opioid containing products

Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx

Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance

60 min **V**
(on each topic)

1. Second generation antihistamines
2. Platelet aggregation inhibitors
3. Pulmonary arterial hypertension (PAH)
4. Inhaled short-acting beta-2 agonists abbreviated review
5. Inhaled anticholinergics
6. Cystic fibrosis
7. Thrombocytopenia
8. Methergine monograph
9. Pyridostigmine monograph

RECONVENE IN OPEN SESSION

ITEM	DESCRIPTION	TIME	VOTE
VI)	Summary of Closed Session <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>	2 min	-
VII)	Medication Request Guidelines <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i> <i>Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx</i>	15 min	V
	<ol style="list-style-type: none"> 1. Atovaquone (Mepron) 2. Blood glucose testing supplies 3. Cialis (tadalafil) for BPH 4. Low Molecular Weight Heparins 5. Hepatitis B drugs 6. Synagis 7. Rifabutin (Mycobutin) 8. Medications for the treatment of Multi-Drug Resistant Tuberculosis 9. PCSK-9 inhibitors 10. ADHD medications recommendations 11. Safety Edit Exception 12. Quantity Limit Exception 13. Cartilagenous Repair Agents 14. Elmiron (pentosane polysulfate sodium) 15. Ezetimibe (Zetia) 16. Modafinil and Armodafinil 17. Altoprev (lovastatin ER) and Fluvastatin, Fluvastatin ER 18. Symlin (pramlintide) 		

VIII) Interim Changes (Consent Agenda)

Natalee Felten, PharmD, Pharmacist, PerformRx

0 min -

Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx

IX) Informational Updates on New Developments in Pharmacy

Natalee Felten, PharmD, Pharmacist, PerformRx

5 min -

Jenna Heath, PharmD, Clinical Pharmacy Supervisor, PerformRx

- New Product Review

X) Public Comment

2 min -

XI) Adjournment

- P&T Committee Member Forms

ACTION / FOLLOW-UP ITEMS

ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS

NEXT MEETING	2019 P&T MEETINGS
March 12th, 2019	June 25 th , 2019
	September 24 th , 2019
	December 17 th , 2019

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.